Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Shares Jump 30 Percent in June to Lead GWDN Index

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Affymetrix climbed 30 percent in June after the firm announced early in the month that Frank Witney had rejoined the company, replacing Kevin King as president and CEO.

Affymetrix, which is currently trading at a 52-week high, led all shares in the GenomeWeb Daily News Index.

Two other firms, Exact Sciences (+15 percent) and Caliper Life Sciences (+13 percent), also rose in the double digits in an otherwise down month for many of the stocks in the Index.

Exact's stock climbed in the past two weeks. Wedbush Securities recently initiated coverage on the firm with an "Outperform" rating and a $10 price target.

Rosetta Genomics had the steepest decline among the stocks that lost ground for the month. Rosetta fell around 33 percent in June and is down 69 percent for the year.

Among the other stocks that dropped significantly during the month were Nanosphere (-29 percent), Accelr8 (-24 percent), and Vermillion (-24 percent).

Overall, the GWDN Index was down nearly 2 percent, matching the drop for both the Nasdaq and Nasdaq Biotech Index. The Dow Jones Industrial Average lost 1 percent.


juneindex.jpg

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.